OUR APPROACH

HOW ONCOLYTIC VIRAL IMMUNOTHERAPY WORKS

Oncolytic viral immunotherapy utilizes engineered viruses that can preferentially infect and kill cancer cells thereby generating de novo or boosting pre-existing anti-tumor immunity to combat cancer. Most oncolytic viruses are genetically modified to enhance tumor tropism or tumor targeting abilities, so that the virus’ virulence against non-tumor cells are significantly reduced. This allows the virus to replicate preferentially in tumor cells and leave normal cells unharmed. 

In addition to direct cell killing abilities, oncolytic viruses can also stimulate a pro-inflammatory environment within the host tumor as well as enhancing antigen release and recognition. This immune activation can counteract the immune evasiveness of tumors. In essence, the virus stimulates a systemic immune response that can combat cancer.

OUR SOLUTION : 

KALIVIR’S ONE VIRUS DELIVERING MULTIPLE THERAPIES

KALIVIR’s novel oncolytic viruses attack cancer in multiple ways to maximize replication of the viruses, spread of the viruses, expression of therapeutic payload matched to specific tumor immunophenotypes and/or unique biomarkers.

• Start with Optimal virus strain for systemic delivery established in the clinic: Vaccinia virus;
• Enhance vaccinia backbone with a proprietary combination of genetic modification to achieve maximize oncolytic killing and systemic delivery and spread;
• Augment the vaccinia backbone with the ability to overcome immunosuppression and to activate anti-tumor immune response to attack tumors;
• Express multiple therapeutic payloads to boost the anti-tumor immune response and that can synergize with other immuno-oncology therapeutics.

MULTIPLE MECHANISMS TO ATTACK CANCER